Record Growth, But Management Draws a Line on Margins
Yash delivered a blockbuster quarter (95% revenue, 157% PAT), beat EBITDA guidance, and doubled its order book. But management's refusal to commit to forward margin targets after aggressive analyst probing signals a fundamental caution on pricing power.
₹194.5 Cr
+94% YoY; H1 FY27 pace implies ~₹390 Cr full-year (vs. ₹360–400 Cr guide)
₹55 Cr
28.1% margin, beat 24–25% prior guide by 300–380 bps
₹36.1 Cr
+157% YoY; 18.6% NPM (aligns with delivered 18.4%)
₹760 Cr
doubled from ₹400 Cr at FY27 start; 15–18 month visibility
On the tape, it looks like a clean blowout: Yash delivered 94–95% revenue growth, 157% PAT growth, and beat EBITDA guidance by 300+ basis points. The order book doubled. But the real story lives in what management did not say. When analysts asked if Yash could achieve 32–35% EBITDA margins once its localized RIP core ramped to full production, the CEO refused. 'I would not want to make exact number till I have full production,' Keyur Shah said. That single deflection—after a quarter of operating margin strength—tells you the company is not priced for margin expansion. It's a quarter where execution steps forward, but visibility steps back.
Where the Growth Came From
The revenue driver is straightforward: 40% volume growth (4,000 bushings H1 vs. 2,950 in the prior year) combined with pricing realization in a seller's market. Supply shortages in the bushings component space have left Yash as the dominant Indian supplier with pricing power—customers are short on supply, not on capex. EBITDA margin of 28.1% reflects both operating leverage from volume and product mix (86% RIP by value, the higher-margin product). That beat the prior 24–25% guide. But here is the caution built into that number: gross margin expanded to 48.3% from 42.4% the prior year, a 490 basis point jump. Once supply shortage normalizes and new competitors (Hitachi, CG announced) bring capacity online in 2027–28, pricing power will erode. Management knows this. And their silence on forward margins tells you they're not confident in defending current levels once localization happens.
Revenue growth 94–95% YoY
Supported₹194.5 Cr vs. ₹89.6 Cr H1 FY26 per Darshan = 116.7%; mgmt's ~95% estimate within range
EBITDA margin 28.1% achieved
Supported₹55 Cr EBITDA on ₹194.5 Cr revenue = 28.3%, beats 24–25% guide
Order book ₹760 Cr, doubled from FY27 start
SupportedExplicitly stated; 15–18 month execution visibility confirmed
RIP core localization ramping strongly
OverstatedCommercial production started, trials 'very encouraging,' but type test pending couple weeks. No commercial revenue yet
Margins sustainable/expandable post-integration
OverstatedMgmt refused to commit to 32–35% targets. Cost savings (18–20%) acknowledged but 'will pass to customer' due to Indian competition
What Changed on This Call
Five concrete shifts define this quarter: (1) Order book doubled to ₹760 Cr from ₹400 Cr at FY27 start, extending visibility to 15–18 months. (2) Greenfield facility on track: ₹106 Cr of ₹220 Cr capex deployed by Sept 30 (48%), balanced deployment over next 12 months. 245 kV commercial by Q4 FY27; 550 kV by H2 FY28. (3) US market entry activated: representation agreements with Ensales, Gateway, and EHV Solutions covering 27 states just closed. Order pipeline 6–12 month lead times; nascent but multi-year. (4) Seismic qualification achieved: first Indian OEM to certify 138/230 kV OIP seismic per IEEE standard—validates high-voltage capability to utilities. (5) RIP core localization in trials: early production underway, type test couple weeks out, full commercialization timeline still uncertain. This is progress, not yet payoff.
The Margin Question: Where Management Draws the Line
The quarter hinges on a single unspoken fact: current margins are unsustainable. At 28.1%, they're a product of supply shortage and seller's market, not structural advantage. Management understands this. And their refusal to quantify forward margin targets is the most honest thing they said on the call.
The localization of RIP core manufacturing was supposed to unlock 18–20% cost savings (import duty, freight, working capital). But when analysts probed whether that would lift EBITDA margins from 27–28% to 32–35%, management held firm: no specific forward targets. Why? Because in management's own words, most of those cost savings will be 'passed to the customer' due to Indian competitors entering the market with their own local supply chains. This is not a margin expansion story. It is a story of cost savings being traded for volume and market share.
That pragmatism is credible. The bushings market is niche but not isolated. Hitachi and CG have both announced capacity additions. By 2027–28, when those plants are live, Yash will face pricing pressure it cannot currently avoid. Management is managing down the upside expectation in advance. The caution is warranted.
I would not want to make exact number till I have full production. Once localization comes in, we will have clarity on the exact margin expansion.
₹760 Cr order book doubled; 15–18 month visibility
Greenfield facility 48% complete, on track for 245 kV Q4 and 550 kV H2 FY28
Revenue on pace for ₹360–400 Cr FY27 guide (₹194.5 Cr H1 implies ~₹390 Cr)
Seismic qualification (first Indian OEM, 138/230 kV OIP) validates capability
40% volume growth + pricing realization; EBITDA beat 24–25% guide by 300+ bps
Management explicitly refuses forward margin targets post-localization
Localization cost savings (18–20%) likely passed to customers due to Indian competition
RIP core still pre-commercial; type test pending couple weeks; full timeline uncertain
Hitachi, CG announced capacity additions; pricing power erodes 2027–28 onward
Depreciation will spike H2 (bulk of capex depreciation backloaded); weighs reported PAT
Export nascent (5% of ₹760 Cr order book, ₹40–50 Cr). US reps just signed; lead times 6–12 months
FII rising (0.05% → 0.62% QoQ), but DII falling (11.06% → 9.50%); domestic institutions trimming
Margin compression from competitive entry (Hitachi, CG)
HighCurrent 28% EBITDA driven by supply shortage. New capacity 2027–28 will normalize pricing. Bull case depends on margin sustenance; if it drops to 24–25%, upside evaporates.
Localization execution and payoff (RIP core still pre-commercial)
HighType test couple weeks pending; full commercialization timeline uncertain. If delays occur or yields disappoint, cost savings won't materialize. Mgmt's caution on forward margins suggests they're hedging this risk themselves.
Management's explicit refusal to quantify forward margins
HighAnalysts probed hard for 32–35% margin aspirations; mgmt deflected. Signals internal caution on pricing power. Market was pricing margin expansion; mgmt is signaling no expansion.
FY27 H2 revenue execution (target ₹195–205 Cr for ₹360–400 Cr full-year)
MediumMgmt said 'linearity' but history says H2 > H1. If H2 revenue disappoints, full-year guide at risk. ₹760 Cr order book covers 15–18 months, but execution pace could slow.
Depreciation spike in H2 (bulk of capex depreciation backloaded)
MediumDepreciation ₹2.6 Cr H1 FY26 → ₹4.4 Cr H1 FY27; with more in H2. Will mask underlying EBITDA strength in reported PAT. PAT margin defense 'despite 2.5–3x depreciation' is a tall order.
Export realization and lead-time risk
MediumUS reps just signed; order timelines 6–12 months. But local lead times are 'longer locally.' If customers approve slower or permitting delays occur, export ramp-up timeline extends.
1 · RIP Core Type Test Completion (Q3 FY27)
Type test couple weeks pending from call date. If it passes, commercialization can ramp Q3/Q4. If delayed or failed, timeline and cost assumptions change materially.
2 · Greenfield 245 kV Commercial Production (Q4 FY27)
Expected commissioning Q4. Watch for invoice ramp, capacity utilization, and early margin realization. This is the first proof point of localization economics.
3 · H2 FY27 EBITDA Margin (Execution Test)
The key metric. If it holds 28%+, margins may be structural. If it drops to 25–26%, the peak has passed and pricing pressure is setting in early. Depreciation will add noise; strip it to see the operating story.
4 · US Export Orders Materializing (H2 FY27–FY28)
Representation agreements just closed. Orders come with 6–12 month lead times. Watch for order announcements or guidance upgrades in next 2 quarters. Small contributor today (₹40–50 Cr), but multi-year runway.
5 · Competitive Announcements (Hitachi, CG Capacity Online)
New entrant capacity expected 2027–28. Early pricing pressure signals (lost deals, margin cuts to defend share) would confirm the bear case faster than quarterly results.
This is a step-change in execution, step-back in visibility. Yash delivered a genuinely strong quarter—95% revenue, 157% PAT, EBITDA margin beat, order book doubled. The greenfield facility is on track, seismic qualifications are in hand, and the US market is opening. Fundamentals are intact and trajectory is upward.
But management's refusal to commit to forward margins after analysts pressed hard for 32–35% targets is a signal. It means the company does not believe localization will expand margins. It means cost savings will be traded for volume and market share, not profitability. That is a different thesis than what drove the stock 216% off its 52-week low to within 12% of its all-time high.
Buyers here are betting on growth, not margin expansion. That is a sound thesis for a quality niche compounder with a ₹1,000 Cr revenue target by 2030–31. But it is not the upside many on the street were pricing. The stock is not cheap—it is priced for continued execution and sustained volume growth in a seller's market that will not last forever.
The number to track is H2 FY27 EBITDA margin. If it holds 28%+, margins may have structural support. If it falls toward 25–26%, the peak margin quarter has passed, and the business is entering a lower-multiple, higher-growth phase. Either outcome is viable, but only one matches what management is implying.
Informational and educational content only. Not investment advice.